In the subacute phase of COVID-19, hospitalized patients displayed cognitive impairment and other neurological defects associated frontoparietal hypometabolism.
Why this matters
Between 37% and 84% of people hospitalized with COVID-19 develop neurological symptoms. Markers of axonal injury and astrocytic activation have also been found in both mild-to-moderate and moderate-to-severe cases. There is a potential that SARS-CoV-2 virions can infect the central nervous system (CNS).
It is known that other peri-infectious encephalopathies can result in cognitive impairment or dementia.